SMi's 4th Annual Pain Therapeutics (K73)

Description

“Growth of the analgesia market is dependent on the introduction of new products. The future of pain therapeutics is bright and the opportunity for investment, biotechnology and pharmaceutical companies to partner in value creation is significant”
Dr Phillip Birch, Chief Scientific Officer, Ionix Pharmaceuticals

Benefits of attending:
ADVANCES IN PAIN THERAPEUTICS: keep up to date with the very latest research
HUMAN/ANIMAL MODELS: understand the need for effective modelling systems
DRUG DISCOVERY: find out about possible new targets for treating pain
TARGET VALIDATION: look at novel techniques for validating potential targets
CLINICAL TRIALS: learn about new approaches to clinical study design
MARKET OPPORTUNITIES: discover the key factors for success of emerging therapies
Day One – 11th June 2003

TRP CHANNEL THERMORECEPTORS AS TARGETS FOR CHRONIC PAIN
9.40 TrpV1 blockers and chronic pain
 The TrpV1 blocker capsazepine (CPZ) shows species selectivity with respect to some of its actions
 CPZ is anti-hyperalgesic when assayed in a susceptible species
 Other TrpV1 blockers may be anti-hyperalgesic
 We and others have discovered other Trp channel thermoreceptors in sensory neurones and skin
 The possibility that these may be involved in pain sensation
Dr Peter McIntyre, Laboratory Head/Program Team Head, Novartis

OPIOIDS
4.00 The use of opioids for the treatment of chronic pain
 Effectiveness of opioids
 Advantages and disadvantages with opioids
 The success of opioid pain relievers
 New generation of opioid painkillers
 Alleviating the side-effects of traditional opioid narcotics
Dr Christine Rauschkolb, Associate Director, Therapeutic Area Neurology, Schwarz BioSciences

CANNABIS-BASED MEDICINES
4.40 The use of cannabis-based medicines in the treatment of pain
 Clinical trials of cannabis-based medicines in pain
 Safety of cannabis-based medicines
 The place of cannabis-based medicines in the management of pain
Dr Nicos Sarantis, Clinical Development Director, GW Pharmaceuticals

CLINICAL TRIALS FOR PAIN: MODELS AND MUDDLES
11.20 Therapeutic needs and drug development
 The role of preclinical models
 The clinical analgesic assay
 Issues with the models: some examples
 The therapeutic gap
 New approaches to some of the issues
Dr Roy Bullingham, Vice President, Global Clinical Pharmacology, Pharmacia/Pfizer